Puerto Rican researcher insists that each advance must be patented for the necessary use in cancer patients.
Dr. Michelle Martínez, associate professor of the Department of Biochemistry of the Central University of the Caribbean. Photo: Medicine and Public Health Magazine.
The patent of the discovery of the researcher and associate professor Dr. Michelle Martínez on the use of medicinal mushrooms in the treatment of cancer of breast, was patented before the Escrow for Science, Technology e Puerto Rican Research (PRSTRT), on behalf of the Central Caribbean University (UCC) and the Canadian company Revive Therapeutics.
Anticancer effect discovered in a mushroom compound
The research was shared with Dr. Fátima Rivas, from St. Jude Children‘s Research Hospital; following the Dr. Martinez discovered that a compound from the variety of mushrooms Ganoderma lucidum, which has an anticancer effect.
“This effect is especially significant once morest breast cancer and has the potential to treat the most aggressive types of breast cancers, such as triple-negative breast cancer and inflammatory breast cancer,” the researchers noted.
The elbow abscess was 4 days before the symptoms, which lasted 15 days before arriving at the ER, it is read or I almost understand that he presented the abscess in the ER, but it was not like that, at home he presented a small abscess that the patient refers open and healthy at home without going to a doctor for evaluation
Los studies reflected both septic arthritis and osteomyelitis, not just arthritis septic Staph Aureus this is responsible for around 53% with MRSA 1/3 of them.
It is read that the patient was discharged very quickly, completed 15 days of IV antibiotics with marked improvement, then coordinated to complete the remaining days of IV antibiotic treatment to complete a minimum of 8 weeks.
Pharmaceutical company will support research
Dr. Martínez stated that she began performing Ganoderma mushroom research lucidum in 2007 and that this represents the goal of every researcher dedicated to science and health.
“Having a pharmaceutical company set out to develop a non-toxic therapeutic alternative for people who suffer from this deadly cancer is a great achievement in my scientific career and as a person. This agreement represents the goal of every researcher: to discover new technologies that help the human health. I want to highlight the support I received from the Central University of the Caribbean and the Trust Technology Transfer Office to make this agreement possible,” said the researcher.
The director of the Technology Transfer Office of the Trust, Dr. David Gulleysaid that this is the first successful license agreement that we have as a product of our collaboration with the UCC.
“The research team also participated in our Therapeutic Accelerator Program 2021 in cooperation with Columbia University, and received $75,000 from the Trust to reduce the risk or “de-risk” the technology. Successful technology transfer starts with outstanding research, but requires a team and resources to move towards commercialization,” she said.
For her part, the president of the UCC, Dr. Waleska Crespo, stated that “this agreement makes history in our institution, as it is the first of the patents developed by UCC researchers to reach the commercialization phase. We are very excited for this achievement and we reaffirm our commitment to the development of knowledge through research, which is one of our institutional goals”.
About the patent
Revive Therapeutics, Ltd. exclusively licensed the international patent application under the name of Biologically Active Ganoderma Lucidum Compounds and Synthesis of Anticancer Derivatives; Ergosterol Peroxide Probes for Cellular Localization. Revive Therapeutics is a life sciences company focused on the research and development of therapies for infectious diseases and rare disorders.
Dr. Martínez explained that the process for the patent began in 2019 with the support of the Trust’s Technology Transfer Office (TTO) and that, following filing a provisional patent, an international patent application (PCT) was submitted. , to seek to protect the invention internationally, and for it to be published, the license talks began in January of this year.
On August 9, the exclusive license agreement on the intellectual property of the discovery was activated.
